Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 7/20 | 0.40 |
| ▸ | MASP2 | O00187 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PPIB | P23284 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432209 | 0.87 | F2 (0.42) | DPP4KCNH2F2MASP2ALDH1A1 | |
| SCHEMBL1432780 | 0.87 | F2 (0.42) | DPP4KCNH2F2MASP2ALDH1A1 | |
| SCHEMBL1901467 | 0.82 | PDPK1 (0.47) | MASP2METPDPK1AKT1AKT2 | |
| SCHEMBL1901471 | 0.82 | PDPK1 (0.47) | MASP2METPDPK1AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1432702 | 0.81 | PDPK1 (0.46) | MASP2METPDPK1AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1432707 | 0.81 | PDPK1 (0.46) | MASP2METPDPK1AKT1AKT2 | |
| SCHEMBL1432630 | 0.80 | DPP4 (0.39) | DPP4KCNH2F2MASP2ALDH1A1 | |
| SCHEMBL1431769 | 0.80 | DPP4 (0.39) | DPP4KCNH2F2MASP2ALDH1A1 | |
| SCHEMBL3150073 | 0.79 | MASP2 (0.40) | DPP4KCNH2F2MASP2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3148336 | 0.79 | PDPK1 (0.47) | DPP4KCNH2MASP2OPRK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | DPP4 1063/4885KCNH2 301/4885F2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.